Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ardelyx Q3 2026 Results: Net Loss of $737K, Loss Narrows

For the nine months ended September 30, 2026, Ardelyx reported total revenues of $343.0 million, a significant increase from $282.1 million in the prior year period, driven primarily by net product sales of IBSRELA and XPHOZAH. Despite the revenue growth, the company recorded a net loss of $55.1 million for the first nine months of 2026, though this was an improvement over the $61.2 million net loss in the same period of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue127.7110.3
Profit before tax-0.6-0.9
Net income-0.7-1.0
EPS (diluted, $ a share)$0.00$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+15.7%
Operating margin3.2%
Source

10-Q filed with the SEC, NASDAQ: ARDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ardelyx, Inc.: key numbers

Share price
$3.07Close, Nov 16
Market cap
$772M
Shares outstanding
251.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ardelyx, Inc.

All →
4:04 PM ET 8-K
Financial Results

Ardelyx Financial Results

Ardelyx reported Q3 2026 total product revenue of $125.5 million, a 19% increase year-over-year, driven primarily by $96.3 million in IBSRELA sales. The company reiterated its full-year 2026 revenue guidance for IBSRELA ($350M-$370M) and XPHOZAH ($110M-$120M) while maintaining a strong cash position of $285.3 million.

Term
Q3 2026

“Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”

Mike Raab, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.